The 57th Japanese Peptide Symposium
Overview
- Symposium Topics
- Chemistry of amino acids, peptides and pseudo-peptides
- Isolation, structure and synthesis of bioactive peptides
- New approaches and strategies for peptide synthesis
- Structural and functional studies of peptides
- Medical and pharmaceutical studies of peptides
- Peptide-related chemical biology
- Application of peptides to biomaterials
- Other studies related widely related to peptide sciences
November 9-11, 2020 | Online conference
Agenda https://www.peptide-soc.jp/57jps/en/program.html Register Fee| Categories | To September 30, 2020 (JST) | From October 1, 2020 (JST) | |
|---|---|---|---|
| General | Japanese Peptide Society, Co-organizer's member | 7,000 JPY | 9,000 JPY |
| Non member | 14,000 JPY | 16,000 JPY | |
| Student | Japanese Peptide Society, Co-organizer's member student | 4,000 JPY | 5,000 JPY |
| Non member | 6,000 JPY | 7,000 JPY |
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE